Stock Pulse
Abbott Laboratories (ABT) reported strong full-year 2024 earnings, exceeding EPS expectations and achieving a 4.6% year-over-year revenue increase to $42 billion [7]. While Q4 revenue growth of 7.2% met expectations, it was the weakest among peers [6], [9]. Despite this, the stock price saw a significant increase after the earnings announcement [9]. Analysts project continued earnings and revenue growth in the coming year, but the stock currently trades at a premium compared to its industry [1], [10]. While a DCF model suggests the stock may be undervalued [2], some analysts express concern about slowing organic revenue growth and shrinking margins [3]. Several insider stock acquisitions related to performance-based awards were also reported [12], [13], [14], [15].